Almirall SA

Almirall SA

Almirall SA

Overview
Date Founded

1997

Headquarters

Ronda General Mitre, 151,Barcelona, Catalonia 08022

Type of Company

Public

Employees (Worldwide)

1,833

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries

Company Description

Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The company operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological and gastrointestinal diseases. The company was founded in 1943 and is headquartered in Barcelona, Spain.

Executives & Employees

Chief Executive Officer

Executive Vice President Finance & Chief Financial Officer

Corporate Director & General Counsel

Executive Vice President R&D & Chief Scientific Officer

Executive Vice President, Global Commercial Operations

Senior Vice President, Corporate Development

Vice President, Legal

Vice President, Manufacturing & Technical Services

Director-Internal Audit

Executive Vice President, Global Commercial Strategy

Board of Directors

Former Partner at Prodes SA

Former Chairman & Chief Executive Officer at Almirall SA

Executive Vice President, Corporate Marketing at Estee Lauder Cos., Inc.

Chair, Dermatology at NYU Langone Health

Former Chief Executive Officer at AstraZeneca Plc

Chief Executive Officer at Almirall SA

Former Partner at Booz Allen Hamilton, Inc.

Professor at Instituto de Estudios Superiores de la Empresa

Former Executive Vice President, Pharmaceutical Operations at Eli Lilly & Company

Venture Partner at Ysios Capital Partners SGEIC SA

Paths to Almirall SA
Potential Connections via
Relationship Science
You
Almirall SA
Owners & Shareholders
Details Hidden

MG is an active, GARP-oriented manager which uses quantitative modeling to manage some of their funds. The firm is benchmark-insensitive and seeks to identify equity value in a systematic way, believing that a stock market index does not necessarily reflect the best available investment opportunities. MG invests in European fixed-income, European mid-cap fixed-income, listed mid-cap European equities, small- to mid-cap European equities, international equity, Spanish equity and large-cap international equities

Details Hidden

Adelphi actively invests in European equity across sectors and market-caps. Their Adelphi Europe portfolio is invested in mid- and large-cap Western European equity. Their Adelphi Emerging Europe strategy is invested across all market capitalisations and industries in Eastern Europe. Both funds follow an equity long/short investment style to maximize absolute returns and minimize volatility. The firm also manages a long-only version of their Adelphi Europe portfolio.Fund managers make the investment decisions, and focus on fundamental research to identify attractive securities.

Details Hidden

Renta 4 is an active, risk-aware manager which does not adhere to a particular investment style in seeking value in their investments, selecting the most appropriate assets, geographic zones, sectors and values on a case-by-case basis.The firm's managers meet daily to share information and make decisions. They aim to maximize return through a systematic risk control process for their investment funds

Recent Transactions
Details Hidden

Grupo Corporativo Landon SL purchases Almirall SA

Details Hidden

Grünenthal GmbH purchases Almirall De Mexico, S.A. De C.V. from Almirall SA

Details Hidden

Almirall SA purchases ThermiAesthetics LLC

Transaction Advisors
Investment Advisor

Advised onAlmirall SA purchases ThermiAesthetics LLC

Legal Advisor

Advised onAlmirall SA purchases Aqua Pharmaceuticals LLC from Roundtable Healthcare Management, Inc.

Legal Advisor

Advised onAlmirall SA purchases Poli Group Holding SRL

Counsel

Advised onAstraZeneca Plc purchases Almirall SA /Respiratory Drugs Business from Almirall SA

Legal Advisor

Advised onAstraZeneca Plc purchases Almirall SA /Respiratory Drugs Business from Almirall SA

Attorney

Advised onAstraZeneca Plc purchases Almirall SA /Respiratory Drugs Business from Almirall SA

Advisors & Consultants
Legal Advisor

Partner at White & Case LLP

Clients

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 0382, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on April 6, 1999 and is headquartered in London, the United Kingdom.

Eczacibasi Pharmaceutical & Industrial Investment Co. is a holding company, which engages in the real estate development, health, personal care, and cosmetics industries. It operates through the following segments: Health, Consumption, and Real Estate Development. The Health segment involves in the production and sale of human health and veterinary medicine. The Consumption segment comprises production, marketing, and sale of consumption products. The Real Estate Development segment includes sale and lease of the real estate projects. The company was founded by M. Nejat Eczacibasi, Melih Eczacibasi, Haluk Eczacibasi, Kemal Eczacibasi, and M. Sakir Eczacibasi on October 24, 1951 and is headquartered in Istanbul, Turkey.

Jeil Pharma Holdings, Inc. engages in the manufacture and sale of pharmaceutical products. Its products include active pharmaceutical ingredients and finished dosage forms. The active pharmaceutical ingredients provide medicines for antibiotic, oncology, cardiovascular, gastrointestinal, neuropsychiatry, urology, endocrinology, respiratory, antiviral, and musculoskeletal. The finished dosage forms of pharmaceutical products provide medicines for cardiovascular, antibiotics, dermal patch, neuropsychiatry, oncology, urology, endocrinology, respiratory, and antiviral. The company was founded on March 7, 1959 and is headquartered in Seoul, South Korea.

Key Stats and Financials As of 2017
Market Capitalization
$1.92B
Total Enterprise Value
$1.41B
Earnings Per Share
$-1.76
Revenue
$639M
Net Profit
$-304M
Total Equity
$1.13B
Total Debt
$250M
Enterprise Value Sales
2.21x
TEVNet Income
-4.65x
EBITDAMargin
0.54%
EBITDA
$3.46M
Enterprise Value EBITDAOperating
408.29x
Three Year Compounded Annual Growth Rate Of Revenue
-6.67%
Five Year Compounded Annual Growth Rate Of Revenue
-1.31%
Debt TEV
0.18x
Investments
Details Hidden

Suneva Medical, Inc. develops, manufactures and commercializes novel, differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. It currently markets ArteFill, ReFissa, Bellafill, and ReGenica Skincare products. The company was founded in April 2009 and is headquartered in Santa Barbara, CA.

Suppliers
GW Pharmaceuticals Plc Pharmaceuticals | Cambridge, CA

GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. It operates through the following segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the commercial products and promotes Sativex through collaborations with pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex, which are using the proprietary cannabinoid technology platform. The company was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.

GlaxoSmithKline Plc Medical Support Services | Brentford, GL

GlaxoSmithKline Plc is a global healthcare company which engages in developing, manufacturing, and marketing of pharmaceutical products including vaccines, over the counter medicines and health-related consumer products. It operates through the following segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded on December 6, 1999 and is headquartered in Brentford, the United Kingdom.

Sinclair Pharma Plc Pharmaceuticals | London, GL

Sinclair Pharma Plc is an aesthetic dermatology company, which provides aesthetic dermatology solutions through collagen stimulation for facial volume loss, thread lifting for facial contouring, and dermal fillers for wrinkles and lines. It operates through the following business segments: Country Operations, and International Operations. The Country Operations segment comprises the proprietary sales infrastructure from the operations in France, the United Kingdom, Italy, Germany, and Spain. The International Operations segment focuses on the sale through a local distributor. The company was founded on May 23, 2011 and is headquartered in London, the United Kingdom.